Brainstorm Cell Therapeutics Faces Delisting Notice
Ticker: BCLI · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00005, $1.00 m |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Brainstorm Cell Therapeutics got a notice about possibly getting delisted. Uh oh.
AI Summary
Brainstorm Cell Therapeutics Inc. filed an 8-K on June 4, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in New York, NY, and is incorporated in Delaware.
Why It Matters
This filing indicates potential issues with Brainstorm Cell Therapeutics' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.
Key Players & Entities
- BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
- June 3, 2024 (date) — Earliest event reported
- June 4, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- New York, NY (location) — Business address city and state
FAQ
What is the specific reason for Brainstorm Cell Therapeutics Inc. receiving a notice of delisting or failure to satisfy a continued listing rule?
The filing does not specify the exact reason for the delisting notice, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing'.
When was this notice of delisting or failure to satisfy a continued listing rule reported?
The report was filed on June 4, 2024, with the earliest event reported being June 3, 2024.
What is the company's state of incorporation and principal business address?
The company is incorporated in Delaware and its business address is 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK, NY 10019.
What is the SEC file number and Central Index Key for Brainstorm Cell Therapeutics Inc.?
The SEC file number is 001-36641 and the Central Index Key is 0001137883.
Has Brainstorm Cell Therapeutics Inc. undergone previous name changes?
Yes, the company was formerly known as GOLDEN HAND RESOURCES INC. (name change date: 20030827) and WIZBANG TECHNOLOGIES INC. (name change date: 20010409).
Filing Stats: 1,053 words · 4 min read · ~4 pages · Grade level 14.9 · Accepted 2024-06-04 06:05:20
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
- $1.00 m — Company was not in compliance with the $1.00 minimum bid price requirement set forth i
Filing Documents
- tm2416355d1_8k.htm (8-K) — 28KB
- 0001104659-24-068007.txt ( ) — 199KB
- bcli-20240603.xsd (EX-101.SCH) — 3KB
- bcli-20240603_lab.xml (EX-101.LAB) — 33KB
- bcli-20240603_pre.xml (EX-101.PRE) — 22KB
- tm2416355d1_8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This Current Report contains forward-looking statements that involve risks and uncertainties intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of current or historical fact contained in this Current Report, including statements regarding the Company's expected timeline for the reverse stock split and compliance with the Nasdaq's Corporate Governance Rules, are forward-looking statements. The words "anticipate," "believe," "continue," "should," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. The Company has based these forward-looking statements on the current expectations about future events held by management. While the Company believes these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond the Company's control. The Company's actual future results may differ materially from those discussed here for various reasons. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this Current Report are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: June 4, 2024 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer